Evidence map›Paper›PMID 29302645›Full record

ArticleAfrican journal of infectious diseases2018

COMMUNITY ACQUIRED PNEUMOCOCCAL PNEUMONIA IN NORTHWESTERN NIGERIA: EPIDEMIOLOGY, ANTIMICROBIAL RESISTANCE AND OUTCOME.

Garba Iliyasu, Farouq Dayyab Mohammad, Abdulrazaq Garba Habib

Abstract read
In one paragraph

Article in African journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Garba IliyasuDepartment of medicine, College of Health Sciences, Bayero University Kano. Kano, Nigeria.
Farouq Dayyab MohammadDepartment of Medicine, Aminu Kano Teaching Hospital. Kano, Nigeria.
Abdulrazaq Garba HabibDepartment of medicine, College of Health Sciences, Bayero University Kano. Kano, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPneumococcus is the leading cause of community acquired pneumonia (CAP) worldwide, and the leading cause of mortality. Pneumococcal pneumonia is poorly studied in Nigeria. We describe the epidemiology including associated co-morbidities and outcome of pneumococcal pneumonia in North-western Nigeria. MATERIAL AND

methodsWe conducted a prospective, hospital based study on patients with community acquired pneumococcal pneumonia. Detailed clinical evaluation and relevant laboratory investigations were carried out. Susceptibility test to commonly used antibiotics was carried out on all confirmed pneumococcal isolates. In hospital mortality was recorded. Analysis was carried out using descriptive statistics with differences and relationships were determined using Chi square and Fisher's exact tests as appropriate, with p < 0.05 regarded as significant.

resultsOf the one hundred and twenty-five (125) patients with pneumococcal pneumonia were studied. The mean age of the patients was 41.3years (± 16.84), and 69/125(55.2%) were males. Co-morbidities were observed in 63/125 (53.8%) of the patients. Resistance to commonly used antibiotics was observed. Overall in-hospital mortality was 9/117(7.8%). HIV (OR=2.081; 95%CI 1.651-3.237), age ≥65years (OR=5.947; 95%CI3.581-17.643), and CURB-65 score of ≥ 3 (OR=2.317; 95%CI1.734-4.719) were independent predictors of mortality.

conclusionPneumococcal pneumonia is the commonest cause of CAP in North-western Nigeria with relatively high mortality. There is need to strengthened the vaccination policy targeting at risk adult population in Nigeria.

Indexed as

Antimicrobial resistanceEpidemiologyOut comePneumococcal pneumonia

Identifiers

PMID29302645
PMCPMC5733253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.